Stockscreener 앱 받기
6.52
2.83%
-0.19
시간 외 거래:
6.50
-0.02
-0.31%
Organon Co 주식(OGN)의 최신 뉴스
L’Association canadienne pour l’équité en santé des femmes et ses partenaires réclament un investissement audacieux dans la santé des femmes afin de combler définitivement les inégalités - GlobeNewswire Inc.
Aviance Capital Partners LLC Takes $599,000 Position in Organon & Co. $OGN - MarketBeat
Institutional Investors May Adopt Severe Steps After Organon & Co.'s (NYSE:OGN) Latest 26% Drop Adds to a Year Losses - 富途牛牛
Organon & Co. $OGN Holdings Cut by Fisher Funds Management LTD - MarketBeat
Organon & Co. Stock Plummets to New 52-Week Low of $6.18 - Markets Mojo
Co. (7XP) stock survive global slowdownQuarterly Risk Review & Real-Time Chart Pattern Alerts - newser.com
Jim Cramer’s “Worst Stock Ever” Might Be Organon (OGN) - MSN
Organon & Co. (OGN) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
KLCM Advisors Inc. Decreases Stake in Organon & Co. $OGN - MarketBeat
Crisis at Organon: Leadership Ousted Amid Sales Scandal - AD HOC NEWS
Tangible book value per share of Organon & Co. – BMV:OGN - TradingView
OGN 8-K/A discloses interim Executive Chair compensation terms - Stock Titan
The Vanguard Group files 13G/A for Organon with 13.82% stake - Stock Titan
Organon & Co. Common Stock (NY: OGN - FinancialContent
Organon stock plunges as CEO resigns amid Nexplanon sales probe - MSN
The Escalator: Organon, Kenvue, Real Chemistry and more - Medical Marketing and Media
Organon & Co. $OGN Shares Acquired by State of New Jersey Common Pension Fund D - MarketBeat
Co. (7XP) stock in 20252025 Sector Review & Safe Entry Point Alerts - newser.com
Organon & Co. (OGN) Stock forecasts - Yahoo! Finance UK
Organon & Co. (OGN) Stock Forecasts - Yahoo! Finance Canada
Organon (OGN) Price Target Decreased by 15.36% to 11.05 - Nasdaq
Organon & Co. (NYSE:OGN) Given Average Rating of "Hold" by Brokerages - MarketBeat
Organon: Critical Assessment Of The Audit Committee Investigation Results (NYSE:OGN) - Seeking Alpha
Organon & Co. (NYSE:OGN) Shares Down 6.2% Following Analyst Downgrade - MarketBeat
Organon Looks For New CEO Amid Investigation Into Front-Loading Contraceptive Implant Sales - Citeline News & Insights
Organon (OGN) Is Down 26.2% After CEO Resignation and Audit Reveals Sales Practice Issues – What's Changed - simplywall.st
Peregrine Capital Management LLC Increases Stock Position in Organon & Co. $OGN - MarketBeat
D.A. Davidson & CO. Sells 50,248 Shares of Organon & Co. $OGN - MarketBeat
Why Organon (OGN) Stock Is Down Today - Yahoo Finance
Organon’s Stock Tumbles Amidst Leadership Shake-Up - StocksToTrade
Organon hit hard over ousted CEO scandal - The Pharma Letter
The Bottom Fishing ClubOrganon: Deep Value In Drugs/Medical Products (NYSE:OGN) - Seeking Alpha
Organon & Co. (NYSE:OGN) Hits New 52-Week Low After Analyst Downgrade - MarketBeat
Organon Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Claims On Behalf of Investors of Organon & Co.OGN - MarketScreener
Organon & Co. (NYSE:OGN) Downgraded by Piper Sandler to Underweight - MarketBeat
Organon Investor Alert: CEO Resigns Amid Audit ProbeSecurities Fraud Investigation on Behalf of Organon InvestorsContact Kehoe Law Firm, P.C.OGN - ACCESS Newswire
Morgan Stanley Maintains Organon & Co(OGN.US) With Hold Rating, Maintains Target Price $10 - 富途牛牛
Organon’s Stock Sinks, But Deep Value Beckons For Patient Investors - Finimize
Organon & Co stock hits 52-week low at 7.26 USD - Investing.com Australia
Organon makes personnel moves after internal probe finds ‘improper’ sales practices - ROI-NJ
Organon appoints interim CEO amid sales practice investigation By Investing.com - Investing.com Canada
Organon & Co.’s Promising Phase 3 Study on Tapinarof Cream for Pediatric Plaque Psoriasis - TipRanks
Organon & Co. (OGN) Faces Investor Scrutiny Amid Improper - GlobeNewswire
Kaplan Fox is Investigating Organon & Co. (OGN) Following an Announcement of Findings of an Audit Committee Investigation and CEO Resignation - NewMediaWire
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 22%. - MSN
Organon CEO resigns after probe into 'improper' sales practices - FirstWord Pharma
Biotech Outshines As Healthcare Stocks See Mixed Moves - Finimize
Organon CEO resigns amid Nexplanon sales probe (updated) - NJBIZ
Organon CEO exits after internal probe over ‘channel stuffing’ to boost sales - Endpoints News
Organon CEO stands down amid contraceptive sales malpractice probe - Yahoo Finance
Stocks making the biggest moves midday: Qualcomm, Fermi, Dyne Therapeutics, Organon, Snowflake and more - CNBC
This Drugmaker Made ‘Improper’ Sales to Meet Guidance. The Stock Plummets 25%. - Barron's
Piper Sandler Downgrades Organon to Underweight From Overweight, $5 Price Target - MarketScreener
Organon Appoints Interim CEO and Board Chair; Reports Results of Audit Committee Investigation - New Jersey Business Magazine
Piper Sandler Downgrades Organon & Co(OGN.US) to Sell Rating, Cuts Target Price to $5 - 富途牛牛
Organon cut to Underweight at Piper Sandler on internal control concerns - Seeking Alpha
Organon Appoints Company Executive Joseph Morrissey as Interim CEO - citybiz
Organon & Co stock hits 52-week low at 7.26 USD By Investing.com - Investing.com South Africa
Organon CEO Resigns After Probe Finds Improper Sales Practices - Bloomberg
1.88%
0.78%
자본화:
|
볼륨(24시간):